Literature DB >> 31109983

A Guide to Understanding Antimicrobial Drug Dosing in Critically Ill Patients on Renal Replacement Therapy.

Valentina Pistolesi1, Santo Morabito2, Francesca Di Mario1, Giuseppe Regolisti3, Chiara Cantarelli3, Enrico Fiaccadori3.   

Abstract

A careful management of antimicrobials is essential in the critically ill with acute kidney injury, especially if renal replacement therapy is required. Acute kidney injury may lead per se to clinically significant modifications of drugs' pharmacokinetic parameters, and the need for renal replacement therapy represents a further variable that should be considered to avoid inappropriate antimicrobial therapy. The most important pharmacokinetic parameters, useful to determine the significance of extracorporeal removal of a given drug, are molecular weight, protein binding, and distribution volume. In many cases, the extracorporeal removal of antimicrobials can be relevant, with a consistent risk of underdosing-related treatment failure and/or potential onset of bacterial resistance. It should also be taken into account that renal replacement therapies are often not standardized in critically ill patients, and their impact on plasma drug concentrations may substantially vary in relation to membrane characteristics, treatment modality, and delivered dialysis dose. Thus, in this clinical scenario, the knowledge of the pharmacokinetic and pharmacodynamic properties of different antimicrobial classes is crucial to tailor maintenance dose and/or time interval according to clinical needs. Finally, especially for antimicrobials known for a tight therapeutic range, therapeutic drug monitoring is strongly suggested to guide dosing adjustment in complex clinical settings, such as septic patients with acute kidney injury undergoing renal replacement therapy.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  CRRT; acute kidney injury; antimicrobials; continuous renal replacement therapy; convection; diffusion; extracorporeal clearance; pharmacodynamics; pharmacokinetics; renal replacement therapy

Year:  2019        PMID: 31109983      PMCID: PMC6658763          DOI: 10.1128/AAC.00583-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  103 in total

Review 1.  Principles of antibacterial dosing in continuous renal replacement therapy.

Authors:  Gordon Choi; Charles D Gomersall; Qi Tian; Gavin M Joynt; Alexander M M Y Li; Jeffrey Lipman
Journal:  Blood Purif       Date:  2010-10-06       Impact factor: 2.614

2.  Mobile infectious disease references: from the bedside to the beach.

Authors:  Steven D Burdette; Robin Trotman; John Cmar
Journal:  Clin Infect Dis       Date:  2012-07       Impact factor: 9.079

3.  Linezolid extracorporeal removal during haemodialysis with high cut-off membrane in critically ill patients.

Authors:  Gianluca Villa; Maria Iris Cassetta; Lorenzo Tofani; Serafina Valente; Cosimo Chelazzi; Silvia Falsini; Angelo Raffaele De Gaudio; Andrea Novelli; Claudio Ronco; Chiara Adembri
Journal:  Int J Antimicrob Agents       Date:  2015-07-26       Impact factor: 5.283

4.  Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.

Authors:  I Bilgrami; J A Roberts; S C Wallis; J Thomas; J Davis; S Fowler; P B Goldrick; J Lipman
Journal:  Antimicrob Agents Chemother       Date:  2010-05-17       Impact factor: 5.191

5.  Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration.

Authors:  Matti Karvanen; Diamantis Plachouras; Lena E Friberg; Elisabeth Paramythiotou; Evangelos Papadomichelakis; Ilias Karaiskos; Iraklis Tsangaris; Apostolos Armaganidis; Otto Cars; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

6.  Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients.

Authors:  R S Malone; D N Fish; E Abraham; I Teitelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

7.  Drug clearance by continuous haemodiafiltration. Analysis of sieving coefficients and mass transfer coefficients of diffusion.

Authors:  H H Vincent; M C Vos; E Akçahuseyin; W H Goessens; W A van Duyl; M A Schalekamp
Journal:  Blood Purif       Date:  1993       Impact factor: 2.614

8.  Dosing guidance for intravenous colistin in critically-ill patients.

Authors:  Roger L Nation; Samira M Garonzik; Visanu Thamlikitkul; Evangelos J Giamarellos-Bourboulis; Alan Forrest; David L Paterson; Jian Li; Fernanda P Silveira
Journal:  Clin Infect Dis       Date:  2016-12-23       Impact factor: 9.079

9.  Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED).

Authors:  Priya Deshpande; Julie Chen; Anita Gofran; Marianna Murea; Ladan Golestaneh
Journal:  Nephrol Dial Transplant       Date:  2010-02-24       Impact factor: 5.992

10.  Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration.

Authors:  S C Wallis; D V Mullany; J Lipman; C M Rickard; P J Daley
Journal:  Intensive Care Med       Date:  2001-04       Impact factor: 17.440

View more
  11 in total

Review 1.  Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses.

Authors:  Ibrahim El-Haffaf; Jean-Alexandre Caissy; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2021-04-20       Impact factor: 6.447

Review 2.  How To Prescribe And Troubleshoot Continuous Renal Replacement Therapy: A Case-Based Review.

Authors:  Javier A Neyra; Lenar Yessayan; Melissa L Thompson Bastin; Keith M Wille; Ashita J Tolwani
Journal:  Kidney360       Date:  2020-12-14

Review 3.  Drug Dosing in Critically Ill Patients with Acute Kidney Injury and on Renal Replacement Therapy.

Authors:  Sai Saran; Namrata S Rao; Afzal Azim
Journal:  Indian J Crit Care Med       Date:  2020-04

4.  Adsorption of vancomycin, gentamycin, ciprofloxacin and tygecycline on the filters in continuous renal replacement therapy circuits: in full blood in vitro study.

Authors:  Dariusz Onichimowski; Krzysztof Nosek; Hubert Ziółkowski; Jerzy Jaroszewski; Aleksandra Pawlos; Mirosław Czuczwar
Journal:  J Artif Organs       Date:  2020-10-08       Impact factor: 1.731

5.  Case Report: Therapeutic Drug Monitoring of Polymyxin B During Continuous Renal Replacement Therapy in Two Pediatric Patients: Do Not Underestimate Extracorporeal Clearance.

Authors:  Caifang Xu; Xiaofen Liu; Yun Cui; Xiaolan Huang; Yu Wang; Yaxin Fan; Hailan Wu; Xin Li; Beining Guo; Jing Zhang; Yucai Zhang
Journal:  Front Pharmacol       Date:  2022-03-24       Impact factor: 5.810

6.  Prolonged exposure to continuous renal replacement therapy in patients with acute kidney injury.

Authors:  Khaled Shawwa; Panagiotis Kompotiatis; Ankit Sakhuja; Paul McCarthy; Kianoush B Kashani
Journal:  J Nephrol       Date:  2021-06-23       Impact factor: 3.902

7.  Pharmacokinetics Alterations in Critically Ill Pediatric Patients on Extracorporeal Membrane Oxygenation: A Systematic Review.

Authors:  Natalia Sutiman; Janine Cynthia Koh; Kevin Watt; Christoph Hornik; Beverly Murphy; Yoke Hwee Chan; Jan Hau Lee
Journal:  Front Pediatr       Date:  2020-06-26       Impact factor: 3.418

8.  Bloodstream infections in critically ill patients: an expert statement.

Authors:  Jean-François Timsit; Etienne Ruppé; François Barbier; Alexis Tabah; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2020-02-11       Impact factor: 17.440

Review 9.  Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy.

Authors:  Lu Li; Xin Li; Yanzhe Xia; Yanqi Chu; Haili Zhong; Jia Li; Pei Liang; Yishan Bu; Rui Zhao; Yun Liao; Ping Yang; Xiaoyang Lu; Saiping Jiang
Journal:  Front Pharmacol       Date:  2020-05-29       Impact factor: 5.810

Review 10.  Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics.

Authors:  Milo Gatti; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2021-06-14       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.